A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma

Cancer Investigation

Volumn 21, Issue 2, 2003, Pages 177-184

  Makower, Della ^a   Sparano, Joseph A ^a   Wadler, Scott ^a   Fehn, Karen ^a   Landau, Leon ^a   Wissel, Paul ^b   Versola, Melissa ^b   Mani, Sridhar ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Adenocarcinoma; Capecitabine; Chemotherapy; Edrecolomab; Monoclonal antibody

Indexed keywords

CAPECITABINE; EDRECOLOMAB;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL SURFACE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; COLON CANCER; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSAMINITIS; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT SELECTION; PILOT PROJECTS;

EID: 0037740991     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120016413     Document Type: Article

References (32)

1. Miwa, M.; Ura, M.; Nishida, M.; Sawada, N.; Ishikawa, T.; Mori, K.; Shimma, N.; Umeda, I.; Ishisuka, H. Design of a novel fluoropyrimidine carbamate, which generates 5-fluroruracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 1998, 34 (8), 1274-1281.
2. Blum, J.L.; Jones, S.E.; Budzar, A.U.; LoRusso, P.M.; Kuter, I.; Vogel, C.; Osterwalder, B.; Burger, H.U.; Brown, C.S.; Griffin, T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 1999, 17 (2), 485-493.
3. Van Custem, E.; Findlay, M.; Osterwalder, B.; Kocha, W.; Dalley, D.; Pazdur, R.; Cassidy, J.; Dirix, L.; Twelves, C.; Allman, D.; Seitz, J.F.; Scholmerich, J.; Burger, H.U.; Verweij, J. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J. Clin. Oncol. 2000, 18 (6), 1337-1345.
4. Cox, J.V.; Pazdur, R.; Thibault, A.; Maroun, J.; Weaver, C.; Jahn, M.W.; Harrison, E.; Griffin, T. A Phase III trial of XELODA (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 1999, 18, 1016.
5. Wenzel, C.; Schmidinger, M.P.; Locker, G.J.; Tomek, S.; Mader, R.M.; Zielinski, C.C.; Steger, G.G. Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer failing immunotherapy. Proc. Am. Soc. Clin. Oncol. 2000, 19, 1457.
6. Cartwright, T. A Phase II trial of Xeloda (capectiabine) in advanced or metastatic pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2000, 19, 1026.
7. XELODA (capecitabine) product label. Roche Laboratories, Inc., 1998.
8. Gottlinger, H.G.; Funke, I.; Johnson, J.P.; Gokel, J.M.; Reithmuller, G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumour therapy: its biochemical nature, tissue distribution, and recognition by different monoclonal antibodies. Int. J. Cancer 1986, 38 (1), 47-53.
9. Adkins, J.C.; Spencer, C.M. Edrecolomab (monoclonal antibody 17-1A). Drugs 1998, 56 (4), 627-628.
10. Frodin, J.E.; Lefvert, A.K.; Mellstedt, H. Pharmacokinetics of the mouse monoclonal antibodies 17-1A in cancer patients receiving various treatment schedules. Cancer Res. 1990, 50 (16), 4866-4871.
11. Herlyn, D.; Sears, H.; Iliopoulos, D.; Lubeck, M.; Douillard, J.Y.; Sindelar, W.; Tempero, M.; Mellstedt, H.; Maher, M.; Koprowski, H. Anti-idiotype antibodies to monoclonal antibody CO17-1A. Hybridoma 1986, 5 (Suppl. 1), S51-S58.
12. Riethmuller, G.; Schneider-Gladicke, E.; Schlimok, G.; Schmiegel, W.; Raab, R.; Hoffken, K.; Gruber, R.; Pichlmaier, H.; Hirche, H.; Pichlmayr, R. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994, 343 (8907), 1177-1183.
13. Gruber, R.; van Haarlem, L.J.; Warnaar, S.O.; Holz, E.; Riethmuller, G. The human anti-mouse immunoglobulin response and the anti-idiotype network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody C017-1A. Cancer Res. 2000, 60 (7), 1921-1926.
14. Fagerberg, J.; Hjelm, A.L.; Ragnhammer, P.; Frodin, J.E.; Wigzell, H.; Mellstedt, H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res. 1995, 55 (9), 1824-1827.
15. Riethmuller, G.; Holz, E.; Schlimok, G.; Schmiegel, W.; Raab, R.; Hoffken, K.; Gruber, R.; Funke, I.; Pichlmaier, H.; Hirche, H.; Bruggisch, P.; Witte, J. Monoclonal antibody therapy for resected Dukes' C colorectal carcinoma: seven year outcome of a multicenter randomized trial. J. Clin. Oncol. 1998, 16 (5), 1788-1794.
16. Braun, S.; Hepp, F.; Kentenich, C.R.; Janni, W.; Pantel, K.; Riethmuller, G.; Willgeroth, F.; Sommer, H.L. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin. Cancer Res. 1999, 52 (9), 701-704.
17. Dresemann, G. Antibody treatment of Dukes C colon carcinoma with minimal residual disease. Proc. Am. Soc. Clin. Oncol. 2000, 19, 968.
18. Schilling, E.M.; Voigtmann, R. Edrecolomab leads to reduction of 17-1A-positive disseminated breast cancer. Proc. Am. Soc. Clin. Oncol. 2000, 19, 1859.
19. Fagerberg, H.; Hjelm, A.L.; Ragnhammer, P.; Frodin, J.E.; Wigzell, H.; Mellstedt, H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res. 1995, 55 (9), 1824-1827.
20. Frodin, J.E.; Harmenberg, U.; Biberfeld, P.; Christensson, B.; Lefvert, A.K.; Rieger, A.; Shetye, J.; Wahren, B.; Mellstedt, H. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. Hybridoma 1988, 7 (4), 309-321.
21. Ragnhammer, P.; Fagerberg, J.; Frodin, J.E.; Hjelm, A.L.; Lindemalm, C.; Magnusson, I.; Masucci, G.; Mellstedt, H. Effect of monoclonal antibody 17-1A and GM-CSR in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int. J. Cancer 1993, 53 (5), 751-758.
22. Sidelar, W.F.; Maher, M.M.; Herlyn, D.; Sears, H.F.; Steplewski, Z.; Koprowski, H. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma 1986, 5 (Suppl. 1), S125-S132.
23. Tempero, M.A.; Sivinski, C.; Steplewski, Z.; Harvey, E.; Klassen, L.; Kay, H.D. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J. Clin. Oncol. 1990, 8 (12), 2019-2026.
24. Fields, A.L.A.; Nagy, A.; Schwartzberg, L.; Punt, C.J.A.; Barton, J.; Barber, L.; Colman, J.R.; Wissel, P.S. Edrecolomab alone or in combination with 5-FU based chemotherapy in adjuvant treatment of stage III colon cancer: a safety review. Proc. Am. Soc. Clin. Oncol. 1999, 19, 1676.
25. Punt, C.J.; Nagy, A.; Douillard, J.; Figer, A.; Skovsgaard, T.; Monson, J.; Barone, C.; Jones, D.; Dethling, J.; Colman, J. Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. Proc. Am. Soc. Clin. Oncol. 2001, 20, 487.
26. Slamon, D.; Leyland-Jones, B.; Shak, S.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Baselga, J.; Norton, L. Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol. 1998, 17, 377.
27. Czuczman, M.S.; Grillo-Lopez, A.J.; White, C.A.; Saleh, M.; Gordon, L.; LoBuglio, A.F.; Jonas, C.; Klippenstein, D.; Dallaire, B.; Varns, C. Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999, 17 (1), 268-276.
28. Link, B.K.; Grossbard, M.L.; Fisher, R.I.; Czuczman, M.; Gilman, P.; Lowe, A.M.; Vose, J.M. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade NHL. Proc. Am. Soc. Clin. Oncol. 1998, 17, 7.
29. Coiffier, B.; Lepage, E.; Herbrecht, R.; Tilly, H.; Solal-Celigny, P.; Munck, J.N.; Bouabdallah, R.; Lederlin, P.; Sebban, C.; Morel, P.; Haioun, C.; Salles, G.; Molina, T. Mabthera (rituximab) plus CHOP is superior to CHOP in elderly patients with diffuse large B cell lymphoma: interim results of a randomized GELA trial. Blood 2000, 96 (Suppl. 1), 950, 223a.
30. Mackean, M.; Planting, A.; Twelves, C.; Schellens, J.; Allman, D.; Osterwalder, B.; Reigner, B.; Griffin, T.; Kaye, S.; Verweij, J. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. 1998, 16 (9), 2977-2985.
31. LoBuglio, A.F.; Saleh, M.N.; Lee, J.; Khazaeli, M.B.; Carrano, R.; Holden, H. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. Clinical aspects. J. Natl Cancer Inst. 1988, 80 (12), 932-936.
32. McLaughlin, P.; Hagemeister, F.B.; Rodrigues, M.A.; Sarris, A.H.; Pate, O.; Younes, A.; Lee, M.S.; Dang, N.H.; Romaguera, J.E.; Preti, A.H.; McAda, N.; Cabanillas, F. Safety of fludarabine, Mitorantrone, and dexamethasone combined with otuximab in the treatment of stage IV indolent lymphoma. Semin. Oncol. 2000, 27 (6 Suppl. 12), 37-41.